Trial Profile
Phase I trial in healthy volunteers of AG 014 bacteria for oral administration of certolizumab as a therapy for inflammatory bowel disease.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Oct 2014
Price :
$35
*
At a glance
- Drugs AG 014 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ActoGeniX
- 29 Oct 2014 New trial record
- 15 Oct 2014 Results published in the Media Release.